['coronary artery disease']
['ticagrelor', 'placebo']

        Inclusion Criteria:

          -  Patients aged ≥40 years with angiographically proven multivessel coronary artery
             disease defined as at least two major epicardial vessels with any combination of
             either (a) >50% luminal stenosis, or (b) previous revascularization (percutaneous
             coronary intervention or coronary artery bypass graft surgery).

          -  Provision of informed consent prior to any study specific procedures

        Exclusion Criteria:

          -  An acute coronary syndrome within the last 12 months

          -  An indication for dual anti-platelet therapy, such as drug eluting stent

          -  Inability to take aspirin

          -  Receiving thienopyridine therapy such as clopidogrel or prasugrel

          -  Percutaneous coronary intervention or coronary artery bypass graft surgery within the
             last 3 months

          -  Inability or unwilling to give informed consent

          -  Woman with child-bearing potential and who are breastfeeding will not be enrolled into
             the trial (woman who have experienced menarche, are pre-menopausal, have not been
             sterilised or who are currently pregnant)

          -  Known hypersensitivity to ticagrelor or one of its excipients

          -  Active pathological bleeding or bleeding diathesis

          -  Significant thrombocytopenia: <100 x 10^9 /L

          -  History of intracranial haemorrhage

          -  Moderate to severe liver impairment (Child's Grade B or C)

          -  Maintenance therapy with strong cytochrome P450 3A4 (CYP3A4) inhibitors, such as
             ketoconazole, nefazodone, ritonavir, indinavir, atazanavir, or clarithromycin

          -  Major intercurrent illness or life expectancy <1 year

          -  Renal dysfunction (eGFR ≤30 mL/min/1.73 m2)

          -  Contraindication to iodinated contrast agents

          -  Planned coronary revascularization or major non-cardiac surgery in the next 12 months

          -  Maintenance therapy with simvastatin at doses greater than 40mg daily

          -  Receiving oral anticoagulants including warfarin, rivaroxaban, dabigatran or apixaban.
      